A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. alleging that company leadership made materially false and misleading statements regarding key operational and regulatory matters over a 14-month period. The complaint focuses on three primary areas of alleged misrepresentation: manufacturing capabilities for the CELLECTRA device, the timeline for INO-3107 biologic license application submission, and the company's overall regulatory prospects.
The lawsuit covers a period spanning from October 2023 through December 2025, during which investors purchased Inovio securities. The allegations suggest that shareholders were not provided with accurate information regarding these critical business developments, potentially affecting investment decisions during this timeframe. The case seeks to recover damages on behalf of eligible investors who acquired the company's shares during the specified period.
Investors who purchased Inovio securities during the alleged misstatement period are encouraged to consider their legal options. The deadline to seek appointment as lead plaintiff in the class action is April 7, 2026. Legal counsel is accepting inquiries from affected shareholders regarding potential participation in the litigation.